{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-040617","form_type":"8-K","ticker":"ACET","cik":"0001720580","company_name":"Adicet Bio, Inc.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.981783+00:00","generated_at":"2026-06-11T22:44:03.354483+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Adicet Q2 net loss $32.4M; ADI-001 shows 71% ORR, 63% CR in Phase 1 NHL","bullets":["Q2 net loss $32.4M ($0.75/share) vs $22.5M ($0.56) in Q2 2022; R&D expenses rose to $28.4M.","ADI-001 Phase 1 data: 71% ORR, 63% CR across all dose levels in heavily pretreated NHL (median 4 prior lines); no DLTs/GvHD.","Plan to initiate pivotal Phase 2 study in post-CAR T LBCL under accelerated approval in 2024; expansion cohort EXPAND starting.","IND for ADI-925 (solid tumors) expected H2 2023; IND for ADI-270 (renal cell carcinoma) expected H1 2024.","Cash $205.5M as of June 30, 2023; runway into H1 2025. Appointed Katie Peng to Board in July."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-040617","json":"https://secwatch.observer/filing/0000950170-23-040617.json","markdown":"https://secwatch.observer/filing/0000950170-23-040617.md","text":"https://secwatch.observer/filing/0000950170-23-040617.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720580/000095017023040617/0000950170-23-040617-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720580/000095017023040617/acet-20230809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T22:44:03.354483+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a0593b779f91adb46d168e339982aca1053ed18c","claim":"Adicet Bio, Inc. reported the quarter ended June 30, 2023 results: net income $32.4 million, EPS $0.75 per basic and diluted share.","evidence_excerpt":"Net loss for the three months ended June 30, 2023 was $32.4 million, or a net loss of $0.75 per basic and diluted share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1720580/000095017023040617/0000950170-23-040617-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Net income","value":"$32.4 million"},{"label":"EPS","value":"$0.75 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}